

David J Moliterno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5601634/publications.pdf>

Version: 2024-02-01

22
papers

5,188
citations

567281

15
h-index

794594

19
g-index

47
all docs

47
docs citations

47
times ranked

6865
citing authors

#	ARTICLE	IF	CITATIONS
1	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	2.8	2,558
2	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	27.0	683
3	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	13.7	537
4	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 2224-2234.	2.8	445
5	Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. Journal of the American College of Cardiology, 2007, 49, 734-739.	2.8	432
6	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. European Heart Journal, 2017, 38, ehw525.	2.2	164
7	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	2.2	93
8	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	2.9	54
9	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	2.2	54
10	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	32
11	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. JAMA Cardiology, 2021, 6, 1032.	6.1	27
12	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e006144.	3.9	24
13	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). American Journal of Cardiology, 2018, 122, 1638-1646.	1.6	19
14	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. European Heart Journal, 2021, 42, 4683-4693.	2.2	18
15	Safety of an abbreviated duration of dual antiplatelet therapy (â‰¥6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2016, 87, 722-732.	1.7	17
16	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology, 2017, 243, 132-139.	1.7	11
17	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq1 1 0.784314 rgBT /Over 2017, 120, 904-910.	1.6	10
18	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thrombosis and Haemostasis, 2019, 119, 1704-1711.	3.4	2

#	ARTICLE	IF	CITATIONS
19	Finding sideline benefits-Of pandemics and same-day-discharge following rotational atherectomy. Catheterization and Cardiovascular Interventions, 2021, 98, 689-690.	1.7	1
20	Coronary interventions among patients with hepatic insufficiency: Encouragement to avoid a jaundiced view. Catheterization and Cardiovascular Interventions, 2020, 96, 811-812.	1.7	0
21	Acute ischemic stroke and the acute need for expansion of stroke teams and their membership. Catheterization and Cardiovascular Interventions, 2021, 97, 475-476.	1.7	0
22	Evolving our learning and application of knowledge to practiceâ€”The ongoing challenges of time and cost in interventional cardiology. Catheterization and Cardiovascular Interventions, 2022, 99, 17-18.	1.7	0